Cancer patients recover after receiving innovative gene therapy in America

 Two patients with chronic lymphocytic leukemia are now cancer-free, after more than a decade of participating in an early trial of a CAR T-cell therapy developed at the University of Pennsylvania that alters genes in the immune system, a study published in the journal Nature on Wednesday confirmed. in the body to target cancer cells.

"CAR T cells remained detectable after more than ten years of infusion, with continued remission in both patients," the journal said, noting that participants "achieved complete stability" after initially receiving treatment during the 2010 trial.

While his team predicted that T cells would be gone from patients' systems "within a month or two," the anti-cancer response lasted longer, Carl John, lead researcher on the trial and co-author of the report told The New York Times.

"Now we can finally say the word 'treatment' using CAR T cells," he added.

T cells are a form of white blood cell that plays a key role in the human immune system, helping to fight cancer cells, viruses, bacteria and other pathogens. The treatment has been approved by the US Food and Drug Administration (FDA).

Follow our latest local and sports news and the latest political and economic developments via Google news